JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Journal: Journal of Clinical Investigation

Published: 2018-04-12

DOI: 10.1172/jci98814

Affiliations: 26

Authors: 55

Go to article
Institutions FC
NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), United States of America (USA) 0.16
NIH Clinical Center, United States of America (USA) 0.13
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA) 0.11
NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), United States of America (USA) 0.09
NIH National Heart, Lung, and Blood Institute (NHLBI), United States of America (USA) 0.07
Eli Lilly and Company, United States of America (USA) 0.07
University Hospital of Münster (UKM), WWU, Germany 0.04
UNC School of Medicine, United States of America (USA) 0.04
University of Arkansas for Medical Sciences (UAMS), United States of America (USA) 0.04
Faculty of Medicine, Hacettepe University, Turkey 0.02
USN Walter Reed National Military Medical Center (WRNMMC), United States of America (USA) 0.02
NIH National Cancer Institute (NCI), United States of America (USA) 0.02
NIH National Institute of Neurological Disorders and Stroke (NINDS), United States of America (USA) 0.02
IWK Health Centre, Canada 0.02
Shaare Zedek Medical Center (SZMC), Israel 0.02
College of Medicine, UNMC, United States of America (USA) 0.02
Riley Hospital for Children, IU Health, United States of America (USA) 0.02
NIH National Human Genome Research Institute (NHGRI), United States of America (USA) 0.02
USC Children's Hospital Los Angeles (CHLA), United States of America (USA) 0.02
La Paz University Hospital, UAM, Spain 0.02
Dr. von Hauner Children's Hospital, LMU, Germany 0.02
Hadassah Medical Center, HUJI, Israel 0.02
UCL Great Ormond Street Institute of Child Health (ICH), United Kingdom (UK) 0.01
Great Ormond Street Hospital for Children NHS Trust, United Kingdom (UK) 0.01

Return